Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A

Rhea-AI Filing Summary

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC report beneficial ownership of 16,244,339 shares of Taysha Gene Therapies, Inc. common stock as of June 30, 2026, representing 5.1% of the class. These shares are held with shared voting power over 16,067,509 shares and shared dispositive power over 16,244,339 shares.

Morgan Stanley Capital Services LLC separately reports 16,001,130 shares, equal to 5.0% of the common stock, all with shared voting and dispositive power. The reporting persons classify themselves respectively as a holding company and a broker-dealer and file jointly under a Joint Filing Agreement.

Key Figures

Shares beneficially owned by Morgan Stanley: 16,244,339 shares Morgan Stanley ownership percentage: 5.1% Morgan Stanley shared voting power: 16,067,509 shares +4 more

7 metrics

Shares beneficially owned by Morgan Stanley 16,244,339 shares Beneficial ownership of Taysha Gene Therapies common stock as of June 30, 2026

Morgan Stanley ownership percentage 5.1% Percent of Taysha Gene Therapies common stock class

Morgan Stanley shared voting power 16,067,509 shares Shares with shared power to vote or direct the vote

Morgan Stanley Capital Services shares 16,001,130 shares Beneficially owned TSHA common shares by Morgan Stanley Capital Services LLC

MS Capital Services ownership percentage 5.0% Percent of Taysha Gene Therapies common stock class

Amendment number Amendment No. 2 Second amendment to Schedule 13G for TSHA

Signature date 08/13/2026 Date signed by Authorized Signatory Claire Gordon

Key Terms

beneficially owned, shared voting power, shared dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 16,067,509.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 16,244,339.00"

parent holding company financial

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

Joint Filing Agreement regulatory

"EXHIBIT NO. EXHIBITS 99.1 Joint Filing Agreement"

FAQ

What percentage of Taysha Gene Therapies (TSHA) does Morgan Stanley report owning?

Morgan Stanley reports beneficial ownership of 5.1% of Taysha Gene Therapies’ common stock. This corresponds to 16,244,339 shares with shared dispositive power as of June 30, 2026.

How many TSHA shares does Morgan Stanley Capital Services LLC report in this Schedule 13G/A?

Morgan Stanley Capital Services LLC reports 16,001,130 shares of Taysha Gene Therapies common stock, representing 5.0% of the class, all with shared voting and shared dispositive power as of June 30, 2026.

What type of SEC filing did Morgan Stanley submit for its TSHA holdings?

The firms submitted an Amendment No. 2 to Schedule 13G for Taysha Gene Therapies (TSHA). This filing updates their beneficial ownership and control information for the company’s common stock.

What voting and dispositive powers does Morgan Stanley have over TSHA shares?

Morgan Stanley reports shared voting power over 16,067,509 shares and shared dispositive power over 16,244,339 shares. It reports no sole voting or sole dispositive power over Taysha Gene Therapies common stock.

How are Morgan Stanley and its subsidiary classified in the TSHA Schedule 13G/A?

Morgan Stanley is classified as an HC (holding company), while Morgan Stanley Capital Services LLC is classified as a BD (broker-dealer). They file jointly, reflecting combined beneficial ownership by specified operating units.

As of what date are Morgan Stanley’s TSHA ownership figures reported?

The ownership figures are reported as of June 30, 2026. The signatures for Morgan Stanley and Morgan Stanley Capital Services LLC are dated August 13, 2026, confirming the information as of that ownership date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 05:38 PM Accepted by SEC EDGAR 08/13/2026 - 05:38 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Taysha Gene Therapies, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

877619106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 877619106

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 16,067,509.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 16,244,339.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,244,339.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 877619106

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 16,001,130.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 16,001,130.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,001,130.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Taysha Gene Therapies, Inc.
(b)	Address of issuer's principal executive offices: 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 877619106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 5.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/13/2026

Morgan Stanley Capital Services LLC

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	08/13/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).